{"result": {"id": "4566d971-c67d-4e59-96cc-824c696bfbfb", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>β受体阻滞剂<|>organization<|>β受体阻滞剂是一种降压药物，通过抑制交感神经活性、心肌收缩力和减慢心率来发挥降压作用。分为非选择性β受体阻滞剂、高选择性β1受体阻滞剂和α1受体/β受体阻滞剂三种亚型。适用于合并冠心病、慢性心力衰竭、主动脉夹层等患者，但可能引起疲乏、肢体冷感等不良反应。)\n##\n(\"entity\"<|>阿替洛尔<|>organization<|>阿替洛尔是一种β受体阻滞剂，预防老年人群脑卒中的效果相对较差，但仍是治疗高血压的常用药物之一。)\n##\n(\"entity\"<|>沙库巴曲缬沙坦<|>organization<|>沙库巴曲缬沙坦是首个ARNI类药物，于2021年6月在中国获批原发性高血压适应证。通过抑制脑啡肽酶对利钠肽的降解，发挥利尿、利钠和扩血管、抗交感神经的效应。)\n##\n(\"entity\"<|>沙库巴曲阿利沙坦<|>organization<|>沙库巴曲阿利沙坦已完成Ⅱ期和Ⅲ期临床试验，是一种正在研发中的ARNI类药物。)\n##\n(\"entity\"<|>LBQ657<|>organization<|>LBQ657是沙库巴曲在体内代谢后的活性物质，参与发挥ARNI类药物的降压作用。)\n##\n(\"relationship\"<|>β受体阻滞剂<|>阿替洛尔<|>阿替洛尔是β受体阻滞剂的一种，用于治疗高血压<|>7)\n##\n(\"relationship\"<|>沙库巴曲缬沙坦<|>沙库巴曲阿利沙坦<|>两者均为ARNI类药物，用于治疗高血压<|>6)\n##\n(\"relationship\"<|>沙库巴曲缬沙坦<|>LBQ657<|>LBQ657是沙库巴曲在体内代谢后的活性物质，参与沙库巴曲缬沙坦的药效发挥<|>8)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558622, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 455, "prompt_tokens": 2452, "total_tokens": 2907, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 660}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 少联合使用。\n　　　(5)β受体阻滞剂 :主要通过抑制过度激活的交感  神经活性、抑制心肌收缩力、减慢心率发挥降压作用。 β受体阻滞剂分为 3种亚型 :非选择性 β受体阻滞剂、 高选择性 β1  受体阻滞剂和 α1  受体/β受体阻滞剂 ,这  三种亚型存在异质性 。与其他降压药相比 , 除了阿替  洛尔预防老年人群脑卒中的效果相对差之外[264]  ,β受  体阻滞剂在预防主要心血管事件方面通常被认为是相  当的[135]  ,依然是治疗高血压的常用药物之一[240] 。\n已有的临床研究和实践表明,β受体阻滞剂的降\n\n\n\n　压疗效在中青年人群相对更好[265-266] ; 不适合用于脉  压明显增大的 ISH。β受体阻滞剂尤其适用于合并冠  心病、既往心肌梗死病史、慢性心力衰竭、主动脉夹层、 伴快速性心律失常、交感神经活性增高(例如静息心  率≥80次/min) [240]  以及高动力状态患者[267] 。该类  药物也是 CKD、围手术期的主要降压药。\n　　　常见的不良反应有疲乏、肢体冷感、胃肠不适等 ,  还可能影响糖、脂代谢 。高选择性 β1 受体阻滞剂对慢  性阻塞性肺疾病(chronic obstructive pulmonary dis- ease, COPD) 是安全的[268]  ,合并糖脂代谢异常患者 ,  可选用 α1 受体/β受体阻滞剂和高选择性 β1 受体阻滞  剂 ,不宜联合使用利尿剂 。二/三度房室传导阻滞、哮  喘患者禁用 ;运动员、周围血管病慎用 。长期应用者突  然停药可发生反跳现象的撤药综合征 ;剂量应在停药  前逐渐减少。\n　　　(6)ARNI:ARNI抑制脑啡肽酶对利钠肽的降解 ,  发挥利尿、利钠和扩血管、抗交感神经的效应[269]  ,其  血管紧张素受体阻断作用可避免脑啡肽酶被抑制后对  RAS的代偿激活 ,起到协同降压作用[269-270] 。沙库巴  曲缬沙坦为首个 ARNI类药物 ,于 2021年 6月在我国  获批原发性高血压适应证 。沙库巴曲阿利沙坦已完成  了 Ⅱ期和 Ⅲ期临床试验[271-272] 。沙库巴曲是前体物  质 ,进入体内后经酶切作用代谢为活性的 LBQ657。 沙库巴曲和缬沙坦以 1 ∶ 1摩尔比例结合构成共晶结  构 。共晶结构避免了两药单独进入人体不能同时被吸  收 ,使两药的吸收与消除速率相近 ,保障了药效发挥的  同步性[273-274] 。\n　　在亚洲和全球的多项研究中 ,与 ARB相比 ,沙库巴  曲缬沙坦可额外使�\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_1e9c60558726e86058ca7ba83578ffdf7b36661936e444a14bbe5cd44deaee8e_v2"}